BioWorld

March 16, 2005

View Archived Issues

Avastin's Survival Data In NSCLC Sends Genentech Soaring, Again

Genentech Inc.'s stock climbed 25 percent in late-day trading Monday after news that a Phase III trial of Avastin met its primary endpoint of survival in non-small-cell lung cancer patients. (BioWorld Today) Read More

ViaCell Gets Patent, Signs Deal With Genzyme; Stock Moves Up

Read More

In Very Early Going, Killing Cancer Cells Indiscriminately

Read More

CVBT Completes IPO, Gets $17M For Vascular Product

Read More

Other News To Note

Read More

Appointments And Advancements

Read More